Market Access and Pricing Asia – Agenda

Day 1


Opening Plenary


13:00
KEYNOTE ADDRESS:
COVID-19 Treatments and Vaccines – Ushering in a New Era for Regulation, Collaboration, and Drug Accessibility

Dr. Andreas Schmidt, Chief Executive Officer, Proteona, Singapore/Germany

13:30
PHARMA LEADERS’ THINK TANK:
Redefining Pharma’s Role in the Global Healthcare Reform Agenda

  • COVID-19 vaccines candidate development
  • Regulations on pandemic drugs approval and accelerated clinical trials under diverse regimes
  • Future of pricing and affordability for Novel Drugs
  • Why technology should be the key component to surviving COVID-19?
  • AI and its immense potential in use of pandemic treatments and early detection

Panellists:
Dr. Sucharita Das, Head of Regulatory Affairs and Quality Assurance APAC, Pfizer, Singapore
Edsel Pereira
, Group Vice President – Information Technology, Glenmark Pharmaceuticals, India
Alexander Zach
, Senior Vice President, Global Head of Market Access and Policy, Biocon, India
Dr. Keith Carpenter
, A*STAR Senior Fellow, Pharma Innovation Programme Singapore (PIPs), Singapore

14:10
Online Networking and Stretch Break


COVID-19 Impacts on Pricing and Access


15:00
COVID-19 Response Dialogue: Accelerating Speed to Market, Drug Accessibility and Affordability

  • Assessing regulator’s priority, managing delays and disruption on appraisals
  • Not so new normal: Impediments to commercialising drugs at the same speed and scale
  • Donation and pricing commitments from pharma manufacturers
  • Developments in Government pricing and reimbursement
  • How will pharma price the affordable therapeutics against COVID-19?

Moderator:
Alexander Zach, Senior Vice President, Global Head of Market Access and Policy, Biocon, India

Panellists:
Yelitte Ho, Australian Pharmacist and Pharmaceutical Policy Advisor, Australia
Sayantani Dasgupta
, Associate Director, Customer Engagement Strategy & Commercial Excellence, Merck, Japan
Viviendouf Koh
, Regional Marketing Manager, South and East Asia, Lundbeck, Singapore
Jek Fong
, Director, Market Access and Personalised Healthcare, Roche, Singapore
More panellists to be confirmed

15:40
Managing the Effects of COVID-19 on Drug Access

  • Propagating international access for drugs
  • Improving access for high cost drugs – will it be the case for coronavirus treatments? -Creating innovative value
  • Overcoming access difficulties in regions

Alexander Zach, Senior Vice President, Global Head of Market Access and Policy, Biocon, India

16:10
Case study of Greater Access – Merck and The Jenner Institute COVID-19 Vaccine Manufacturing

  • Redefine, transform and innovate pharma business strategy for greater access
  • Adjusting commercial models- patient-physician relationships
  • Catering to high population markets

Sayantani Dasgupta, Associate Director, Customer Engagement Strategy & Commercial Excellence, Merck, Japan

16:40
Gilead Science Case Study:
COVID-19: Ramping up Remdesivir Production for Affordable Access and Pricing

17:10
Roche’s Case Study: Approaches for Urgency to Market in the Fight Against COVID-19

  • Beyond the antibody test
  • Case study- drug development and access acceleration

Jek Fong, Director, Market Access and Personalised Healthcare, Roche, Singapore

End of Virtual Conference Day 1

Day 2


Agile Market Access


13:00
Agile and Increased Capability for Market Access for Non-COVID Drugs

  • Working in the era of changed business models, price negotiation and FDA’s shifting priorities
  • Strengthening regional health systems with partnerships
  • Regional case studies- challenges and opportunities
  • Strategies to introduce biosimilars into Asia

Mark Tennyson, JAPAC Regional Head, Value, Access and Policy, Amgen, Hong Kong

13:30
Dealing with COVID-19 and Drug Access in Indonesia

  • Managing access and supply disruption for usual drugs
  • Pricing and gaining access for COVID-19 related drugs
  • Product commercialisation risks during and post-COVID

Rizman Abudaeri, Director, Market Access, Government and Regulatory Affair, AstraZeneca, Indonesia

14:00
Fair Pricing and Drug Affordability Whilst Satisfying Governments Healthcare Policy  

  • ASEAN and Asia market analysis
  • Working with different reimbursement regimes – Aiming for a Win-Win situation
  • Managing drug development costs, investments and ROIs
  • Improving drug access and copayment- What is the right balance?
  • Developed vs emerging market landscapes: What are the key considerations for growth

Moderator:
Jun Feng
, Market Access Associate Director, Oncology, JAPAC, AbbVie, Singapore  

Panellists:
Mark Tennyson
, JAPAC Regional Head, Value, Access and Policy, Amgen, Hong Kong
Nathan K
, Market Access and Government Affairs Director, Johnson & Johnson, Malaysia
Judy Deng
, Head of Market Access, Oncology, Novartis, China
Rizman Abudaeri, Director, Market Access, Government and Regulatory Affair, AstraZeneca, Indonesia

14:40
China’s Drug Landscape – The Medical Insurance Reform of Tripartite System and Implications for Market Access

  • Access for innovative therapies in China
  • What are CFDA’s priorities?
  • Practical considerations and negotiations for placement onto the list of National Reimbursement Drug List (NRDL)
  • Proving value for innovative therapies
  • China case study: Managing access for cancer drugs post COVID-19 outbreak

Judy Deng, Head of Market Access, Oncology, Novartis, China

15:00
Online Networking and Stretch Break

15:30
Early access of rare disease treatment: balance between financial sustainability and social responsibility

Carol Chu, Head of VD&A, Communication and Patient Advocacy, Shire

16:00
Oncology Market Access and Pricing Strategies – Addressing Risks in  Commercialisation

Jun Feng, Market Access Associate Director, Oncology, JAPAC, AbbVie, Singapore

16:30
Global Strategy on Pharma Marketing and Agile Product Launch Strategy

For speaking enquiry, please contact Yvonne.Leong@informa.com

17:10
Oncology and COVID-19: Setting the Priority Right

  • Building access to cancer care in emerging markets
  • India’s case study: Rat race between oncology drugs and COVID-19
  • Building portfolio and connecting with customers
  • Using digital tools and access strategies

Anupama Rao Singh, Director, Oncology and Hospital CoE, Global Generics, Emerging Markets, Dr Reddys, India

17:40
End of Day 2 Virtual Conference                                                                                                                                                                              

Day 3


Payer and Reimbursement


13:00
Case Study:
Lundbeck’s Value Creation Strategies in Asia 

  • Working with payers, patients and reimbursement bodies for creating customer-focused values
  • Value creation for disease area of psychiatry
  • Lowering stigma for treatments in neurology and psychiatry

 Viviendouf Koh, Regional Marketing Manager, South and East Asia, Lundbeck, Singapore

13:30
Pharma Partnerships for Affordable Healthcare 

For speaking enquiry, please contact Yvonne.Leong@informa.com

14:00
Australia Case Study:
COVID-19 Government, Reimbursement & Regulatory Updates 

  • COVID-19 in Australia
  • Universal access to healthcare in Australia and the Pharmaceutical Benefits Scheme (PBS)
  • Universal Subsidy Scheme for Medicines
  • How does a drug get listed on the PBS (registration process, pricing, listing consideration)?
  • Key factors influencing decision making by the independent Pharmaceutical Benefits Advisory Committee
  • Patent and data protection of pharmaceuticals in Australia

Yelitte Ho, Australian Pharmacist and Pharmaceutical Policy Advisor, Australia   


Optimising RWE and HTA         


 14:30
Demonstrating Value and Data Gathering for RWE in Asia

  • Understand how RWE is different from randomized control trials (RCTs)
  • How do Regulatory bodies consider the use of RWE for decision making?
  • Challenges to collect RWE; how to access and when to use do we have that ready in Asia
  • Successful regional case studies

Kim Soyoung, Director HEOR, Medical Affairs, Asia & Oceania, Astellas Pharma, Singapore

15:00
Online Networking and Stretch Break

15:30
Use of Real-World Evidence in the Drug Registration Process 

  • What’s real World Data, Real world Evidence?
  • How is Real World Evidence generated?
  • Overview of Regulations (US FDA, EMA, China NMPA)

Gaelle Richer, Director Global Regulatory Affairs, GSK, Singapore

16:00
HTA for Growing Economies

  • Challenges and Opportunities of using HTA
  • Key areas of focus for emerging markets
  • Maximising the returns of HTA on proving drug value

Nathan K, Market Access and Government Affairs Director, Johnson & Johnson, Malaysia


Diversity and Inclusion in Pharma


16:40
Cultivating the Next-Gen of Women Leaders in Pharma

  • Why does gender equality matter on the board?
  • Key challenges facing women leaders in Pharma
  • Management efforts to address some of these challenges, and remaining gaps
  • Reflections on the journey to the top
  • Breaking the glass ceiling: Lessons learnt along the way, and advice to my younger self
  • Management efforts to address some of these challenges, and remaining gaps

Panelists:
Anupama Rao Singh
, Director, Oncology and Hospital CoE, Global Generics, Emerging Markets, Dr. Reddy’s Laboratories, India
Angela Brady
, Director of Innovation Research, APAC R&D, GSK, Singapore
Chandana Yeluri, Head- Digital and Continuous Improvement, Sandoz Development Center, Novartis, India
More panelists to be confirmed

17:40
End of Day 3 Virtual Conference